CancerVax Corp.
This article was originally published in Start Up
Executive Summary
CancerVax has developed a vaccine comprised of three irradiated melanoma cell lines that appear to be highly immunogenic and appear to cause an immune response in most patients with melanoma.
You may also be interested in...
Serono Deals Its Way Into Oncology
It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.
Cancer Vaccines: European Immunotherapy Strategies
European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.